Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW: Zolbetuximab plus CAPOX in Advanced Gastric or GEJ Adenocarcinoma
NCT03653507Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Nov 2018
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Zolbetuximab plus CAPOX with Placebo plus CAPOX (2 arms). Primary endpoint: Progression-Free Survival. Started Nov 2018; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03653507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653507.